Literature DB >> 29184476

Organ-Preserving Strategies for the Management of Near-Complete Responses in Rectal Cancer after Neoadjuvant Chemoradiation.

Patricio B Lynn1, Paul Strombom1, Julio Garcia-Aguilar1.   

Abstract

In recent years, organ preservation has been considered a feasible alternative to total mesorectal excision for patients with locally advanced rectal cancer with a clinical complete response to neoadjuvant therapy. However, the degree of tumor response to neoadjuvant therapy is variable. A fraction of the patients who did not achieve a complete response had grossly visible tumors. These patients, with clearly incomplete clinical response, need a total mesorectal excision. In addition, some patients with a significant tumor response still have some abnormalities in the bowel wall, such as superficial ulceration or tissue nodularity, which, while not conclusive for the presence of a tumor, are indicative of the possibility of a residual tumor in the bowel wall or in mesorectal lymph nodes. The management of patients with a so-called near-complete clinical response to neoadjuvant therapy is controversial. In this article, we will review the clinical and radiological criteria that define a clinical response to neoadjuvant therapy, possible treatment strategies, and follow-up protocols. We will also discuss patient and tumor characteristics that in our opinion can be useful in selecting the most appropriate treatment alternative. Although organ preservation and quality of life are important, the primary goal of treatment for these patients should be local tumor control and long-term survival.

Entities:  

Keywords:  local excision; near-complete clinical response; neoadjuvant chemoradiation; rectal cancer

Year:  2017        PMID: 29184476      PMCID: PMC5703665          DOI: 10.1055/s-0037-1606117

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  46 in total

1.  Population-based analyses of lymph node metastases in colorectal cancer.

Authors:  Rocco Ricciardi; Robert D Madoff; David A Rothenberger; Nancy N Baxter
Journal:  Clin Gastroenterol Hepatol       Date:  2006-09-18       Impact factor: 11.382

2.  Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.

Authors:  Julio Garcia-Aguilar; Oliver S Chow; David D Smith; Jorge E Marcet; Peter A Cataldo; Madhulika G Varma; Anjali S Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R Hunt; Michael J Stamos; Charles A Ternent; Daniel O Herzig; Alessandro Fichera; Blase N Polite; David W Dietz; Sujata Patil; Karin Avila
Journal:  Lancet Oncol       Date:  2015-07-14       Impact factor: 41.316

3.  Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.

Authors:  J V Schou; F O Larsen; L Rasch; D Linnemann; J Langhoff; E Høgdall; D L Nielsen; K Vistisen; A Fromm; B V Jensen
Journal:  Ann Oncol       Date:  2012-04-02       Impact factor: 32.976

4.  Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Gregory Wynn; John Marks; Hermann Kessler; Joaquim Gama-Rodrigues
Journal:  Dis Colon Rectum       Date:  2010-12       Impact factor: 4.585

5.  Multi-modality approach in curative local treatment of early rectal carcinomas.

Authors:  M J Hershman; A Sun Myint; C A Makin
Journal:  Colorectal Dis       Date:  2003-09       Impact factor: 3.788

6.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies.

Authors:  Fausto Petrelli; Giovanni Sgroi; Enrico Sarti; Sandro Barni
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

7.  Depth and lateral spread of microscopic residual rectal cancer after neoadjuvant chemoradiation: implications for treatment decisions.

Authors:  F M Smith; H Wiland; A Mace; R K Pai; M F Kalady
Journal:  Colorectal Dis       Date:  2014-08       Impact factor: 3.788

8.  Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer.

Authors:  Marjun P Duldulao; Wendy Lee; Leanne Streja; Peiguo Chu; Wenyan Li; Zhenbin Chen; Joseph Kim; Julio Garcia-Aguilar
Journal:  Dis Colon Rectum       Date:  2013-02       Impact factor: 4.585

9.  Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.

Authors:  In Ja Park; Y Nancy You; John M Skibber; Miguel A Rodriguez-Bigas; Barry Feig; Sa Nguyen; Chung-Yuan Hu; George J Chang
Journal:  Dis Colon Rectum       Date:  2013-02       Impact factor: 4.585

10.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

View more
  6 in total

Review 1.  Non-operative management of rectal cancer: understanding tumor biology.

Authors:  Iris H Wei; Julio Garcia-Aguilar
Journal:  Minerva Chir       Date:  2018-05-24       Impact factor: 1.000

Review 2.  Nonoperative Management for Rectal Cancer.

Authors:  Felipe F Quezada-Diaz; J Joshua Smith
Journal:  Hematol Oncol Clin North Am       Date:  2022-05-11       Impact factor: 2.861

Review 3.  Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial.

Authors:  Paolo Goffredo; Felipe F Quezada-Diaz; Julio Garcia-Aguilar; J Joshua Smith
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

4.  Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence.

Authors:  Karen Benezery; Lucile Montagne; Ludovic Evesque; Renaud Schiappa; Jean-Michel Hannoun-Levi; Eric Francois; Brice Thamphya; Jean-Pierre Gerard
Journal:  Clin Transl Radiat Oncol       Date:  2020-07-06

5.  Survey results of US radiation oncology providers' contextual engagement of watch-and-wait beliefs after a complete clinical response to chemoradiation in patients with local rectal cancer.

Authors:  Jehan Yahya; Daniel Herzig; Matthew Farrell; Catherine Degnin; Yiyi Chen; John Holland; Simon Brown; Christina Binder; Jerry Jaboin; Vassiliki Liana Tsikitis; Nima Nabavizadeh; Charles R Thomas; Timur Mitin
Journal:  J Gastrointest Oncol       Date:  2018-12

Review 6.  Re-staging and follow-up of rectal cancer patients with MR imaging when "Watch-and-Wait" is an option: a practical guide.

Authors:  Inês Santiago; Bernardete Rodrigues; Maria Barata; Nuno Figueiredo; Laura Fernandez; Antonio Galzerano; Oriol Parés; Celso Matos
Journal:  Insights Imaging       Date:  2021-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.